Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease | Sarcoidosis, Vasculitis and Diffuse Lung Diseases

Yukiko Miura

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan

Takefumi Saito

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Kazutaka Fujita

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Toru Tanaka

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Yoshiya Tsunoda

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Arata Azuma

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Takahito Nei

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Yohei Yatagai

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Shigen Rin

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Akimasa Sekine

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Kenji Hayashihara

Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Keywords

Antifibrotic agent, interstitial lung disease, pirfenidone, scleroderma, vital capacity

Abstract

Interstitial lung disease is the most common complication and cause of death among patients with scleroderma. Scleroderma-related interstitial lung disease has usually been treated with cyclophosphamide; however, its effect was evaluated to be modest and long-term administration of this drug is associated with adverse effects. Herein, we report our clinical experience of administering pirfenidone, which is an antifibrotic agent, in five patients with scleroderma-related interstitial lung disease. All patients demonstrated an increase in vital capacity.

Abstract 169 | PDF Downloads 152

PDF

Published

Oct 20, 2014

How to Cite

1.

Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2014 Oct. 20 [cited 2024 Apr. 19];31(3):235-8. Available from: https://www.mattioli1885journals.com/index.php/sarcoidosis/article/view/3326

Issue

Vol. 31 No. 3 (2014)

Section

Case Series

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Author Biographies

Yukiko Miura, Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan

Department of Pulmonary Medicine and Oncology, an assistant professor

Takefumi Saito, Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Department of Respiratory Medicine, clinical professor

Kazutaka Fujita, Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Department of Respiratory Medicine, MD

Toru Tanaka, Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Department of Respiratory Medicine, MD

Yoshiya Tsunoda, Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Department of Respiratory Medicine, MD

Arata Azuma, Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Department of Pulmonary Medicine and Oncology, professor

Takahito Nei, Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi Hospital, Japan

Department of Pulmonary Medicine and Oncology, MD

How to Cite

1.

Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2014 Oct. 20 [cited 2024 Apr. 19];31(3):235-8. Available from: https://www.mattioli1885journals.com/index.php/sarcoidosis/article/view/3326

Download Citation

Most read articles by the same author(s)

Marc A. Judson, Ulrich Costabel, Marjolein Drent, Athol Wells, Lisa Maier, Laura Koth, Hidenobu Shigemitsu, Dan A. Culver, Jeffrey Gelfand, Dominique Valeyre, Nadera Sweiss, Elliott Crouser, Adam S. Morgenthau, Elyse E. Lower, Arata Azuma, Mami Ishihara, Shin-ichiro Morimoto, Tetsuo Tetsuo Yamaguchi, Noriharu Shijubo, Jan C. Grutters, Misha Rosenbach, Hui-Ping Li, Paola Rottoli, Yoshikazu Inoue, Antje Prasse, Robert P. Baughman, The WASOG Sarcoidosis ORGAN ASSESSMENT INSTRUMENT INVESTIGATORS, The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool , Sarcoidosis, Vasculitis and Diffuse Lung Diseases: Vol. 31 No. 1 (2014)
Robert P. Baughman, Jan Grutters, Athol Wells, Arata Azuma, Ulrich Costabel, Marjolein Drent, Elyse Lower, Daniel Culver, World Association for Sarcoidosis and Other Granulomatous Disease (WASOG) Centers of Excellence , Sarcoidosis, Vasculitis and Diffuse Lung Diseases: Vol. 38 No. 4 (2021)
Ryo Okuda, Eri Hagiwara, Takuma Katano, Satoshi Ikeda, Akimasa Sekine, Hideya Kitamura, Tomohisa Baba, Koji Okudela, Kenichi Ohashi, Takashi Ogura, Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome , Sarcoidosis, Vasculitis and Diffuse Lung Diseases: Vol. 36 No. 1 (2019)
Hiroki Hayashi, Takahito Nei, Shinji Abe, Yoshinobu Saito, Nariaki Kokuho, Kenichiro Atsumi, Kazue Fujita, Takefumi Saito, Takahiro Tanaka, Akihiko Gemma, Arata Azuma, Body Mass Index and Arterial Blood Oxygenation as Prognostic Factors in Patients with Idiopathic Pleuroparenchymal fibroelastosis , Sarcoidosis, Vasculitis and Diffuse Lung Diseases: Vol. 34 No. 1 (2017)
Yoshinori Kamata, Hiroshi Sato, Kensuke Joh, Yoshinori Tsuchiya, Shinobu Kunugi, Akira Shimizu, Tsuneo Konta, Robert P Baughman, Arata Azuma, Clinical characteristics of biopsy-proven renal sarcoidosis in Japan , Sarcoidosis, Vasculitis and Diffuse Lung Diseases: Vol. 35 No. 3 (2018)
Naoyuki Kuse, Shinji Abe, Hiroki Hayashi, Koichiro Kamio, Yoshinobu Saito, Jiro Usuki, Arata Azuma, Shoji Kudoh, Akihiko Gemma, Long-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective analysis , Sarcoidosis, Vasculitis and Diffuse Lung Diseases: Vol. 33 No. 3 (2016)
Hiroshi Mochimaru, Yuh Fukuda, Arata Azuma, Kazuhiro Osanai, Yoshinobu Saito, Tomoko Mochimaru, Akihiko Gemma, Reconsideration of discrepancies between clinical and histopathological features in acute eosinophilic pneumonia , Sarcoidosis, Vasculitis and Diffuse Lung Diseases: Vol. 31 No. 4 (2014)